To obtain a therapeutic medicine effective for uveitis, especially endogenous uveitis, by using a specific methotrexate derivative as an active ingredient.

This medicine for treating uveitis contains one or more kinds of a compound of formula I [R1 is CH2, CH2O, CH2S, CH2SO; R2 is H, an alkyl, benzyl; R3 is COOR4 (R4 is H, an alkyl), NHCOR5 (R5 is phenyl), etc.,; (n) is 1-4] and its salts as active ingredients. The medicine for treating uveitis also contains one or more kinds of a compound of formula II (R8, R9 are each H, an alkyl) and its salts as active ingredients. The active ingredient is e.g. N-[1-[(2,4-diamino-6-pteridinyl) methyl]-3,4-dihydro-2H-1,4-benzothiazine-7- carbonyl]-L-α-aminoadipic acid. The medicine is especially preferably orally administered. The medicine is usually administered at a daily dose of approximately 0.01-100mg/person. The medicine can locally be administered and is preferably administered in the form of an eye drop or injection.